Clinical Trial: Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07852221) titled 'Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation' on Sept. 08.

Brief Summary: Atrioventricular node ablation with permanent pacing (the "pace-and-ablate" strategy) controls ventricular rate in atrial fibrillation that has not responded to drug therapy or catheter ablation. Chronic right ventricular pacing, however, can cause pacing-induced cardiomyopathy (PICM), and it is not well established which patients are at risk and should therefore receive conduction system pacing or biventricular pacing instead.

REPACE is a multicentre retrospective cohort of consecutive patients who underwent atriov...